Introduction
============

Muscular dystrophies are heterogeneous, hereditary neuromuscular disorders and are associated with frame-disrupting or missense mutations in several genes involved in muscular structure and function [@B1]. Mutations in the *dysferlin* gene, encoding a 230 kDa transmembrane protein implicated in membrane fusion and repair [@B2], are linked to clinically distinct muscle diseases, i.e., limb-girdle muscular dystrophy type 2B (LGMD2B), Miyoshi myopathy (MM) and distal myopathy with anterior tibial (DMAT)[@B3], [@B4],which are also collectively referred to as dysferlinopathy, and are characterized by wasting and weakness of skeletal muscle. Dysferlinopathy generally manifests after puberty with variable severity in different muscles [@B5]. Currently no therapy is available for dysferlinopathic patients [@B6]. Transfecting functional truncated variants of *dysferlin* genes in animal models has proven successful at restoring membrane repair, yet has failed to arrest progressive muscle wasting. This suggests that the full-length dysferlin protein maybe required to reverse disease progression [@B7][@B8].However, the large size of the *dysferlin* gene represents a challenge for gene transfer approaches, since most viral vectors used in gene therapy have a limited cargo capacity. Although adeno-associated virus (AAV) vector systems have been developed to deliver full-length or nano-sized *dysferlin* genes into dysferlin-deficient mice and non-human primates with encouraging results [@B9], [@B10], AAV can trigger immune response that limits its therapeutic efficacy upon repeat treatment. Recent studies have made some progress in correcting the deficiency by inducing stable expression of full-length dysferlin integrated in dysferlin-deficient myoblasts using sleeping beauty transposons. Transfected myoblasts grafted in immune-deficient mice exhibited normal regenerative capabilities *in situ*. Although such *ex vivo* therapeutic approaches appear attractive, they require substantial development prior to clinical applications [@B11].

Exosomes are membranous nanovesicles with diameters of 50-150nm, which are secreted by various types of cells upon fusion of multi-vesicular bodies with the plasma membrane [@B12]. Exosomes are known to be intercellular messengers and can shuttle cargoes such as proteins, lipids, mRNA and microRNAs between cells [@B13]; thus, exosomes have been extensively used for diagnostic and therapeutic purposes [@B14]. Antigen-carrying tumor exosomes were shown to activate dendritic cells and elicited effective regression in hepatocellular carcinoma and other tumor models [@B15], [@B16]; while exosomes from neurons can shuttle endogenous proteins such as alpha-synuclein oligomers and amyloid-β (Aβ) in neurodegenerative diseases [@B17], [@B18]. Proteomic analysis of exosome-like vesicles released from C2C12 myoblasts and myotubes revealed protein involved in the regulation of myoblast fusion, membrane repair and regeneration [@B19]. Fusion of exosomes with a target cell membrane could also facilitate the exchange of membrane proteins between two cell types [@B20], [@B21]. Thus, exosomes could potentially deliver therapeutic proteins in dysferlinopathy.

Considering the unique features of exosomes, e.g., low immunogenicity and scalability, exosomes have been extensively employed to carry therapeutic moieties [@B22]. Here, we present evidence that exosomes derived from dysferlin-expressing muscle cells or serum are capable of delivering full-length dysferlin protein and may be useful for treating dysferlinopathy. The lack of dysferlin protein in urine exosomes derived from dysferlinopathic patients also presents non-invasive diagnostic opportunities for dysferlinopathy compared to the dysferlin Western blots from muscle biopsy that are currently necessary for confirmation of diagnosis.

Materials and Methods
=====================

Cell culture
------------

Immortalized murine H2K, A/J, BL6 and dysferlin-deficient H2K cells were kindly provided by Professor Terry Partridge (Children\'s National Medical Center,Center for Genetic Medicine Research,Washington DC, US) and cultured as previously reported [@B23], [@B24], [@B25]. Briefly, cells were grown in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 20% fetal calf serum (FBS), 2% chick embryo extract, 2% L-glutamine, 1% penicillin and streptomycin and 20U/mL mouse recombinant IFN-γ (Invitrogen, US) at 33°C in 10% CO~2~. Immortalized human myoblasts were kindly provided by Professor Jennifer Morgan (University College London, Institute of Child Health, London, UK) and were cultured in skeletal muscle cell growth medium (PromoCell, Germany) supplemented with 1.5% GlutaMAX (Gibco, US), 20% FBS and 1% penicillin and streptomycin. Myotubes were obtained from confluent H2K, dysferlin-deficient H2K or human myoblasts seeded in gelatin-coated 12-well plates after 3 days of serum deprivation at 37°C under a 5% CO~2~ atmosphere (DMEM with 5% horse serum (HS, Hyclone, US)). Murine C2C12 cells and NIH 3T3 cells were kept in house and grown at 37°C in 5% CO~2~ in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin.

Preparation and purification of exosomes
----------------------------------------

Cell culture medium was sequentially centrifuged at 1000 × g for 10 min, followed by 10,000×g for 30 min. The supernatant was collected and filtered with a 0.22µm filter (Millex, Germany), followed by ultracentrifugation at 100,000×g for 1 h to pellet exosomes. Exosome pellets were washed in a large volume of PBS and recovered by centrifugation at 100,000×g for 1 h. The total protein concentration of exosomes was quantified by the Bradford assay (Sangon Biotech, China). For human serum and urine exosome isolation, human serum and urine were obtained from healthy volunteers (provided by Tianjin Blood Center, Tianjin, China) and dysferlinopathic patients (provided by Peking Union Medical College Hospital, Beijing, China, approved by the hospital ethic committee, Permit No. JS-1317) and centrifuged at 3000×g, 6000×g and 10,000×g twice for 30 min each time to remove cell debris, followed by filtration with 0.22µm filter (Millex, Germany). The supernatant was transferred into a fresh tube and further pelleted by ultracentrifugation (Beckman Optimal-100 XP, Beckman Coulter, Germany) at 100,000×g for 1 h. Exosome pellets were washed in a large volume of PBS and recovered by ultracentrifugation at 100,000×g for 1 h. Exosomes were purified by sucrose density gradient centrifugation as previously reported [@B26]. Briefly, the gradients were centrifuged for 18 h at 100,000×g at 4°C. Six fractions from 0.65-1.65 M sucrose gradients were collected and ultracentrifuged at 100,000×g for 1 h at 4°C to pellet exosomes. The exosome pellets were dissolved in PBS and the total protein concentration of exosomes was quantified by the Bradford assay (Sangon Biotech, China).

Characterization of exosomes
----------------------------

The size distribution of exosomes was measured using a nanoparticle tracking and zeta potential distribution analyzer (Paricle Metrix-PMX, Germany) and the morphology of the exosomes was visualized using a high-resolution transmission electron microscope (TEM, Hitachi HT7700, Tokyo, Japan). Briefly, the re-suspended exosomes were mixed with an equal volume of 4% paraformaldehyde (PFA) and adsorbed onto a glow-discharged, carbon-coated formvar film, which was attached to a metal specimen grid. Excess solution was blotted off and the grid was immersed with a small drop (50 μL) of 1% glutaraldehyde for 5 min followed by washing with 100 μL still water 2 min each time for 8 times. Subsequently, the grid was transferred to 50 μL uranyl-oxalate solution (pH7.0) for 5 min and then 50 μL methyl cellulose-uranyl acetate (100 μL 4% uranyl acetate and 900 μL 2% methyl cellulose) for 10 min on ice. The excess solution was blotted off and the sample was dried and examined in the TEM.

Exosome uptake assay
--------------------

To test the uptake of exosomes derived from H2K myotubes in dysferlin-deficient H2K myoblasts, exosomes (5 μg) labelled with membrane dye PKH67 (Sigma, US) were incubated with dysferlin-deficient H2K myoblasts cultured in differentiation medium containing 2% pre-centrifuged HS. Cells were observed and photographed using a conventional fluorescence microscope (Olympus FV1000, Olympus, Japan) at 0, 4, 8, 12, 24 and 48 h after incubation. For detection of the localization of exosomes in dysferlin-deficient H2K myotubes, 5 μg PKH67-labelled exosomes were incubated with dysferlin-deficient H2K myotubes for 48 h at 37°C in 5% CO~2~. Subsequently, cells were incubated with HBSS solution supplemented with the membrane dye FM4-64 (2.5 μM, Molecular Probes, Invitrogen, US) at 37°C for 5 min, followed by washing and visualization using a confocal fluorescence microscope (Olympus FV1000, Olympus, Japan).

Digestion of exosomes
---------------------

To evaluate the location of dysferlin protein in exosomes, 25 μg exosomes derived from H2K myotubes were incubated with 0.025% trypsin (Sigma, US) and /or 0.1% saponin (Sigma, US) for 5 min at 37°C, followed by heating at 100°C for 3 min to terminate the digestion reaction, and were then analyzed by Western blot assay.

Protein extraction and western blotting
---------------------------------------

Exosome and cell pellets were lysed in lysis buffer (125 mM Tris-HCl, pH6.8, 10% sodium dodecyl sulfate (SDS), 2M urea, 20% glycerol and 5% 2-mercaptoethanol) and subjected to 10% SDS-polyacrylamide gel electrophoresis and gels were transferred to a PVDF membrane. Membranes were blocked in 5% skimmed milk and probed with primary antibodies including mouse monoclonal antibody to the C-terminus of dysferlin (1:200, NovoCastra, US), rabbit monoclonal antibodies to the N-terminus of dysferlin (1:1000, Abcam, UK) and Cytochrome C (1:1000, Cell Signaling Technology, US), rabbit polyclonal antibodies for CD63 (1:200, Santa Cruz, US), CD9 (1:1000, Abcam, UK) or goat polyclonal antibody for Alix (1:200, Santa Cruz, US) overnight at 4°C. GAPDH (1:1000, Cell Signaling Technology, US) was used as a loading control. The bound primary antibody was detected by horseradish peroxidase-conjugated goat anti-mouse IgG (Sigma, US), goat anti-rabbit IgG (Sigma, US) or rabbit anti-goat IgG (Sigma, US), respectively. The ECL western blotting analysis system (Millipore, Billerica, MA) was applied.

Immunocytochemistry and confocal microscopy
-------------------------------------------

H2K and dysferlin-deficient H2K myoblasts were seeded in 6-well plates and differentiated into myotubes as described above. Cells were washed with cold PBS twice and fixed with 4% PFA for 30 min at room temperature (RT) and subjected to permeabilization with 0.1% Triton X-100 at RT for 30 min. Subsequently, cells were blocked with 5% BSA for 1 h at RT and incubated with primary antibodies, including rabbit monoclonal antibody to dysferlin (1:50, Abcam, UK) or mouse monoclonal antibody to caveolin-3 (1:100, Santa Cruz, US), overnight at 4°C. Goat anti-rabbit Alexa Fluor 594 and goat anti-mouse Alexa Fluor 488 secondary antibodies (Invitrogen, US) were used with a dilution of 1:200 in PBS for 1 h at RT and nuclei were counterstained with DAPI (Invitrogen, US). Images were obtained using a confocal fluorescence microscope (Olympus FV1000, Olympus, Japan).

Membrane repair assay
---------------------

The membrane repair assay was performed as previously reported [@B25], [@B27]. Briefly, 100 μg exosomes derived from H2K myotubes were incubated with H2K or dysferlin-deficient H2K myotubes for 48 h. Myotubes were washed twice with HBSS solution (140mM NaCl, 5mM KCl, 2mM CaCl~2~, 1mM MgCl~2~·6H~2~O, 10mM HEPES and 10mM glucose, pH7.4) prior to membrane wounding, and then incubated with HBSS solution containing membrane dye at 37°C for 5 min. The laser wounding experiment was performed in HBSS solution supplemented with the FM4-64 dye (2.5 μM, Invitrogen, US). A two-photon confocal laser-scanning microscope (Olympus, Japan) was used for laser injury and a 2.0μm^2^ area overlapping the plasma membrane was irradiated at 25% of the maximum output power of the laser operating at 850nm for 200ms. X-Y images were captured with a 63x water immersion objective at 10s intervals for 300s. The mean fluorescence intensity of FM4-64 at the site of damage was measured with the Olympus imaging software. The fluorescence intensity was normalized to the pre-wound intensity and the normalized response (ΔF/F0) was plotted as a function of time. For each treatment, at least five different myotubes per well (triplicates for each experiment, the experiment was repeated 3 times) were used for the membrane repair assay.

Scrape wounding and surface exposure of LAMP1 luminal epitopes
--------------------------------------------------------------

Dysferlin-deficient H2K myotubes were incubated with exosomes derived from H2K myotubes (100 μg) in the differentiation medium for 48 h, followed by washing with PBS twice. Cells were injured by dragging a scalpel blade four times across the surface of the dish in the presence of 1mg/mL Texas Red dextran (Invitrogen, US) in HBSS solution containing 2mM CaCl~2~. Subsequently, dishes were transferred to 37°C and incubated for 5 min to allow membrane repair. Cells were washed with cold PBS twice and fixed for 30 min at RT with 4% PFA and blocked with 5% BSA for 1 h at RT. Then cells were incubated with primary rat monoclonal anti-LAMP1 antibody (1:100, Santa Cruz, US) overnight at 4°C,followed by labelling with secondary antibody goat anti-mouse Alexa Fluor 488 for 1 h at RT, and then nuclei were counterstained with DAPI (Invitrogen, US). Images were obtained on an inverted fluorescence microscope (Olympus IX71, Olympus, Japan).

Imaging Ca^2+^ influx into cells after laser injury
---------------------------------------------------

H2K and dysferlin-deficient H2K myotubes were incubated with 100 μg exosomes derived from H2K myotubes for 48 h. Myotubes were washed twice with HBSS solution (140mM NaCl, 5mM KCl, 2mM CaCl~2~, 1mM MgCl~2~·6H~2~O, 10mM HEPES and 10mM glucose, pH7.4) and incubated with HBSS containing Fluo-3 AM (5 μM, Beyotime, China) for 30 min at 37°C. Subsequently, the dye was removed and cells were washed twice with HBSS and incubated with HBSS for another 15 min at 37°C to ensure that the Fluo-3 AM was completely transformed into Fluo-3. Cells were then laser injured in HBSS as described above. X-Y images were captured with a 63x water immersion objective at 4s intervals for 250s. The mean fluorescence intensity of Fluo-3 was measured with the Olympus imaging software. The kinetics of Ca^2+^ influx was normalized to the pre-wound intensity and the normalized response (ΔF/F) was plotted as a function of time. For each treatment, the detection was performed on at least six different myotubes per well (triplicates per treatment, the experiment was repeated 3 times).

Myotube counts
--------------

H2K and dysferlin-deficient H2K myoblasts were cultured in differentiation medium in the presence of 50 μg exosomes derived from H2K myotubes for 48 h. Images were obtained on an inverted fluorescence microscope (Olympus FV1000, Olympus, Japan). The number of myotubes was examined using an inverted fluorescence microscope and quantified by counting myotubes in five fields for each treatment in a double-blinded manner (triplicates for each treatment and the experiment was repeated for 3 times). Multinucleated and tube-like myotubes were counted.

Generation of human dysferlin-deficient myoblasts
-------------------------------------------------

Immortalized normal human myoblasts (kindly provided by Professor Jennifer Morgan, University College London, Institute of Child Health, London, UK) were transfected with CRISPR/Cas9-expressing lentivirus (Lentiviral CRISPR Toolbox, Zhanglab, US), followed by 2 µg/mL blasticidin selection for 1week. Cas9-expressing myoblasts were transfected with sgRNA-expressing lentivirus for 12 h, followed by 0.5 µg/mL puromycin selection for 2 weeks. sgRNAs targeting human *dysferlin* gene exons 22 and 55 were designed with the CRISPR/Cas9 Target Online Predictor (crispr.cos.uni-heidelberg.de, University of Heidelberg, Germany). The human *dysferlin* gene exon 22 and exon 55 target sgRNA sequences were 5\'-GAAGGCGCAGTGCTCCACGG-3\' and 5\'-CTGGTGAAGCCCTTCAGCTG-3\', respectively. These sgRNAs were cloned into a LentiGuide-puro vector at BsmBI site as previously reported [@B28].

Statistical analysis
--------------------

All data are reported as mean values±SEM. Statistical differences between treatment and control groups were evaluated by SigmaStat (Systat Software, London, UK). Both parametric and non-parametric analyses were applied, in which the Mann-Whitney rank sum test (Mann-Whitney *U*-test) was used for samples with a non-normal distribution, whereas a two-tailed *t*-test was performed for samples with a normal distribution, respectively.

Results
=======

Dysferlin is abundant in myotube-derived exosomes
-------------------------------------------------

To explore if exosomes carry dysferlin, we examined the presence of dysferlin in exosomes derived from different murine muscle cell lines and a non-muscle cell line 3T3 was used as a negative control. As exosomes from the immortalized muscle cell line H2K showed the highest levels of dysferlin compared to other muscle cells (Fig. [S1](#SM0){ref-type="supplementary-material"}A), H2K cells were used hereafter. Higher levels of dysferlin were detected in exosomes derived from differentiated myotubes (EXOdysf) than from undifferentiated myoblasts (EXOmyob) (Fig. [1](#F1){ref-type="fig"}A), synchronous with cellular expression (Fig. [S1](#SM0){ref-type="supplementary-material"}B), though the yield of EXOdysf (20 µg) was lower than EXOmyob (60 µg of protein per 3x10^6^ cells in 48 h). EXOdysf showed a typical sauce-cup shape under transmission electron microscopy (TEM) (Fig. [1](#F1){ref-type="fig"}B), with a peak size of 114.3 nm as shown by nanoparticle tracking analysis (NTA) (Fig. [1](#F1){ref-type="fig"}C). Interestingly, levels of dysferlin protein in exosomes derived from myotubes at different time-points after induction of differentiation varied, with day 6 myotubes showing the highest expression (Fig. [S1](#SM0){ref-type="supplementary-material"}C); therefore, day 6 myotubes were used hereafter.

To investigate whether dysferlin is located inside or loosely associated on the surface of EXOdysf, we treated EXOdysf with 0.25% trypsin. Protein loosely attached to the surface of EXOdysf would be degraded. A clear dysferlin band appeared in the samples treated with trypsin when probed with antibodies targeting either the N-terminus (cytoplasmic region) or C-terminus (intracellular domain proximal to the transmembrane domain) of dysferlin protein (Fig. [1](#F1){ref-type="fig"}D), indicating that dysferlin is not nonspecifically attached to exosomes. In contrast, the dysferlin band diminished when EXOdysf were treated with 0.25% trypsin and 0.1% saponin, a membrane-permeabilizing detergent [@B29](Fig. [1](#F1){ref-type="fig"}D), suggesting that dysferlin is located inside the lumen of EXOdysf.

EXOdysf anchors dysferlin on the membrane of DYSF^-/-^ myotubes
---------------------------------------------------------------

To evaluate whether EXOdysf can be taken up by and transfer dysferlin to dysferlin-deficient muscle cells (DYSF^-/-^), we incubated PKH67-labelled EXOdysf (5 µg) with DYSF^-/-^ myotubes and monitored fluorescence at different time-points after unincorporated EXOdysf were removed. Fluorescence was readily detectable at 4 h and peaked at 24 h after incubation (Fig. [S2](#SM0){ref-type="supplementary-material"}A). Examination on the localization of PKH67-labelled EXOdysf in DYSF^-/-^ myotubes 24 h after incubation indicated that the majority of EXOdysf are internalized into the cytoplasm with some present on the membrane (Fig. [S2](#SM0){ref-type="supplementary-material"}B), suggesting that EXOdysf can be efficiently absorbed into DYSF^-/-^ myotubes. Consistently, dysferlin protein was detected in DYSF^-/-^ myotubes after the addition of EXOdysf (Fig. [2](#F2){ref-type="fig"}A). Immunostaining revealed that some restored dysferlin proteins were membrane-bound and partly co-localized with Caveolin-3, a membrane protein associated with dysferlin during the formation of caveolae and repair vesicles [@B30] (Fig. [2](#F2){ref-type="fig"}B), demonstrating that EXOdysf can transfer and anchor dysferlin on DYSF^-/-^ myotube membranes.

EXOdysf restores cellular function of DYSF^-/-^ myotubes
--------------------------------------------------------

As dysferlin is integral in the membrane repair process in muscle cells [@B31], we explored if membrane resealing function can be restored by EXOdysf. We introduced FM4-64, a membrane-impermeable dye, into DYSF^-/-^ myotubes following laser injury and monitored FM4-64 uptake at different time-points. Bright fluorescence was observed at 50s, peaking at 250s after injury in untreated DYSF^-/-^ myotubes (Fig. [3](#F3){ref-type="fig"}A). Strikingly, faint signals, comparable to wild-type (WT) myotubes, were detected in DYSF^-/-^ myotubes treated with EXOdysf (Fig. [3](#F3){ref-type="fig"}A). Quantification of the cellular uptake of FM4-64 indicated a significant decrease in fluorescence intensity in EXOdysf-treated DYSF^-/-^ myotubes compared to untreated DYSF^-/-^ myotubes (Fig. [3](#F3){ref-type="fig"}B), suggesting that this effect is potentially due to the restored dysferlin. Lysosomal exocytosis is associated with repair of injured cell membrane; however, docking and calcium-triggered fusion of lysosomes are impaired in DYSF^-/-^ myotubes [@B32]. We investigated if intracellular lysosome-associated membrane protein-1 (LAMP-1), a lysosomal marker protein, localized to the surface of injured myotubes after repair. As expected, LAMP-1 was detectable on the surface of EXOdysf-treated DYSF^-/-^ and WT myotubes, but not on untreated DYSF^-/-^ myotubes 300s after scrape wounding (Fig. [3](#F3){ref-type="fig"}C), suggesting that dysferlin-harboring cytoplasmic vesicles aggregate to fuse with the injured membrane.

Also, dysferlin is composed of multiple Ca^2+^-sensitive C2 domains that are implicated in regulation of vesicle fusion, trafficking and membrane repair [@B33]. In the absence of dysferlin, mechanical stress or membrane injury will result in massive influx of Ca^2+^ and disruption of Ca^2+^ homeostasis [@B34]. To investigate whether EXOdysf can regulate the homeostasis of Ca^2+^ flux in DYSF^-/-^ myotubes after laser-induced membrane injury, we monitored the level of Ca^2+^ change in the cytosol with Fluo-3AM, a fluorescent Ca^2+^ probe [@B35]. A sharp rise in intracellular Ca^2+^ (i.e., a "Ca^2+^ spike") was observed in DYSF^-/-^ myotubes 5s after injury, whereas a much milder increase in the fluorescence intensity was detected in EXOdysf-treated DYSF^-/-^ myotubes (Fig. [3](#F3){ref-type="fig"}D, E). The fluorescence intensity declined gradually and reached pre-injury values for EXOdysf-treated DYSF^-/-^ myotubes at 50s after injury, but not for untreated DYSF^-/-^ myotubes (Fig. [3](#F3){ref-type="fig"}D, E), suggesting that EXOdysf enables the regulation of Ca^2+^ influx in DYSF^-/-^ myotubes.

Serum exosomes restore human DYSF^-/-^ myotube membrane repair capacity
-----------------------------------------------------------------------

To investigate whether dysferlin-expressing exosomes can restore dysferlin in dysferlinopathic patients, we generated human DYSF^-/-^ myoblasts harboring different mutations in the *dysferlin* gene exons 22 and 55 by introducing frame-disrupting insertions or deletions with clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9 system. Analysis of genomic sequence and dysferlin protein expression confirmed that the *dysferlin* gene was efficiently disrupted (Fig. [S3](#SM0){ref-type="supplementary-material"}A, B), with no morphological alterations found compared to normal human myoblasts (data not shown). As dysferlin expression had been reported in peripheral blood monocytes [@B36], [@B37], we examined if the level of dysferlin expression in normal human serum exosomes may be therapeutically useful. Strikingly, dysferlin protein was also abundant in exosomes from normal human serum (EXOser) (Fig. [4](#F4){ref-type="fig"}A), with a typical sauce-cup shape under TEM (Fig. [S3](#SM0){ref-type="supplementary-material"}C) and a peak size of 123.4 nm in diameter (Fig. [S3](#SM0){ref-type="supplementary-material"}D). Dysferlin protein was readily detectable in human DYSF^-/-^ myotubes 48 h after the introduction of EXOser (Fig. [4](#F4){ref-type="fig"}B), demonstrating that EXOser can efficiently transfer dysferlin to human DYSF^-/-^ cells. To examine the functionality of EXOser, we added FM4-64 dyes into human DYSF EXO55^-/-^ and EXO22^-/-^ myotubes in the presence of EXOser following laser injury. As expected, fluorescence signals appeared around the injury sites at 50s after injury in untreated human DYSF EXO55^-/-^ and EXO22^-/-^ myotubes and peaked at 250s (Fig. [4](#F4){ref-type="fig"}C). However, much less fluorescence was found in EXOser-treated human DYSF EXO55^-/-^ and EXO22^-/-^ myotubes subjected to laser injury (Fig. [4](#F4){ref-type="fig"}C). Quantitative analysis revealed significant decreases in cellular uptake of FM4-64 dyes in EXOser-treated DYSF EXO55^-/-^ and EXO22^-/-^ myotubes compared to untreated myotubes at different time-points (Fig. [4](#F4){ref-type="fig"}D), indicating that EXOser confers the ability of membrane repair to human DYSF^-/-^ myotubes. These findings support the conclusion that the compromised membrane repair capacity of human DYSF^-/-^myotubes can be restored.

Serum and urine exosomes present diagnostic value for dysferlinopathic patients
-------------------------------------------------------------------------------

Dysferlin expression in blood monocytes was reported to correlate with dysferlin levels in skeletal muscle both in healthy controls and dysferlinopathic patients [@B38]. To assess if dysferlinopathic patients can be differentiated from healthy controls based on serum exosome dysferlin, we collected serum from dysferlinopathic patients and examined levels of dysferlin protein in patient serum exosomes. Strikingly, a clear dysferlin protein band appeared in exosomes from normal human serum, but no signal was detected in exosomes from dysferlinopathic patients (Fig. [5](#F5){ref-type="fig"}A). To validate this approach, we collected serum from another 19 dysferlinopathic patients with confirmed diagnosis by gene sequencing (Fig. [5](#F5){ref-type="fig"}B) and /or immunohistochemistry (Table [1](#T1){ref-type="table"}). The absence of dysferlin protein in exosomes derived from 19 dysferlinopathic patients using Western blot (Fig.[5](#F5){ref-type="fig"}C) confirmed that serum exosomes can be employed to differentiate dysferlinopathic patients from healthy controls. As dysferlin protein was found in human urine exosomes previously [@B39], we harvested exosomes from human urine, which showed a typical saucer-cup shape (Fig. [S4](#SM0){ref-type="supplementary-material"}A) and a peak size of 94.3 nm in diameter (Fig. [S4](#SM0){ref-type="supplementary-material"}B), and examined the expression of dysferlin. Concordantly, dysferlin was also detected in urine exosomes derived from normal controls but not from dysferlinopathic patients (Fig. [5](#F5){ref-type="fig"}D, E). Since dysferlin protein analysis is essential to confirm specific protein deficits and diagnosis, the data provide evidence that urine exosomes can be employed as a non-invasive diagnostic tool for dysferlinopathic patients.

Discussion
==========

In this study, we demonstrated that exosomes derived from myotubes or human serum carry dysferlin and can efficiently transport functional dysferlin to murine and human dysferlin-deficient muscle cells, restoring their membrane repair capacities in response to injury. Importantly, the lack of dysferlin protein in exosomes from dysferlinopathic patients\' serum and urine enables the identification of dysferlinopathic patients non-invasively, which is particularly attractive compared to the current standard - muscle biopsy. This is the first proof-of-concept study showing the capability of exosomes as carriers for endogenous dysferlin protein not only for treatment but also as a non-invasive tool for diagnosis of dysferlinopathy.

Dysferlin-expressing exosomes can restore the expression of dysferlin and cellular function of human dysferlin-deficient muscle cells bearing different mutations in the *dysferlin* gene, indicating the clinical relevance and general applicability of this approach. Further functional evaluation and toxicological studies on dysferlin-expressing exosomes in dysferlin-null mouse models are warranted to develop this therapeutic modality further. Dysferlin was particularly abundant in human serum exosomes with a concentration of 200 µg exosomes per mL of blood. This supports the notion that serum exosomes can be used as a treatment option for dysferlinopathic patients considering that a large volume of serum (at least 400 mL) can be drawn from a healthy donor or close relatives to lower the chances of potential immunogenicity and thus provide a timely intervention for dysferlinopathic patients.

Dysferlinopathy is a rare disease with an estimated prevalence of 1 in 15,000 individuals (data from Jain foundation), varying geographically [@B40]. In this study, we were able to recruit 22 dysferlinopathic patients with confirmed diagnosis characterized by typical clinical manifestations, defined *dysferlin* gene mutations, and muscle biopsies in one single medical center, and this is a relatively large cohort of patients. The *dysferlin* gene mutation types identified here are similar to dysferlinopathic cases deposited in the database such as UMD-DYSF mutations and Leiden Muscular Dystrophy databases, further confirming that there is no racial difference for dysferlinopathy. Consistent with the clinical data, dysferlin is absent in serum or urine exosomes from dysferlinopathic patients but present in exosomes from their parents (Patient No. 20), supporting the conclusion that exosomes from serum or urine can be used as a reliable non-invasive diagnostic tool, particularly for urine exosomes.

We demonstrated that dysferlin protein is specifically sorted into exosomes and can be efficiently transferred to and localized correctly on the membrane of dysferlin-deficient muscle cells and confer the membrane repair capability of dysferlin-deficient myotubes in response to injury. It was reported previously that the absence of dysferlin delays the differentiation of human dysferlin-deficient myoblasts *in vitro* [@B41]; the presence of more myotubes when dysferlin-expressing exosomes were added in the dysferlin-deficient myoblasts supports the notion that dysferlin contribute to the differentiation of myoblasts (Fig. [S5](#SM0){ref-type="supplementary-material"}), though other secondary effects cannot be excluded. Also, our results imply that transplantation of dysferlin-positive myotubes may be able to "treat" surrounding muscle cells via exosomes, making cell therapy more plausible.

In conclusion, we demonstrate that dysferlin-expressing exosomes can be employed as carriers for endogenous dysferlin protein and can restore cellular functions of dysferlin-deficient muscle cells irrespective of mutations. Lack of dysferlin in urine exosomes from dysferlinopathic patients provides evidence for the use of urine exosomes as a non-invasive diagnostic tool for dysferlinopathy.

Supplementary Material {#SM0}
======================

###### 

Supplementary figures.

###### 

Click here for additional data file.

The authors acknowledge Dr. Xiaoming Feng and Ms. Wanzhu Yang (Tianjin Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China) for assistance with two-photon experiments and Dr. Yiqi Seow (Biomedical Sciences Institutes, A\* STAR, Singapore) for critical review of the manuscript. This study was funded by Chinese National Basic Research Program (973) (No.2017YFC1001902), National Natural Science Foundation of China (Grant No. 81672124, 81671528, 81501531 and 81361128013), Tianjin Municipal Science and Technology Key Project (Grant No. 14JCZDJC36000 and 14JCQNJC11000) and Tianjin Municipal 13^th^ five-year plan (Tianjin Medical University Talent Project).

Author contributions
====================

X.D. and H. Y. designed the research and analyzed the data. X. D., X. G., Y. D. and N. R. performed the experiments. H. Y. supervised the research. H. Y. wrote the manuscript with input from all authors.

DYSF^-/-^

:   dysferlin-deficient

LGMD2B

:   limb-girdle muscular dystrophy type 2B

MM

:   miyoshi myopathy

DMAT

:   distal myopathy with anterior tibial

NTA

:   nanoparticle tracking analysis

EXOdysf

:   exosomes derived from differentiated myotubes

EXOmyob

:   exosomes derived from undifferentiated myoblasts

LAMP-1

:   lysosome-associated membrane protein-1

EXOser

:   exosomes from normal human serum.

![**Characterization of exosomes derived from murine myotubes (EXOdysf).** (**A**) Western blot to examine the level of dysferlin expression in EXOdysf. 20 μgor 50 μg total protein from cell lysates or exosomes was loaded and Cytochrome C was used as an organelle marker. (**B**) Representative transmission electron microscopy (TEM) image of EXOdysf (scale bar = 200 nm (left) or 100 nm (right)).Arrowheads point to the typical sauce-cup shape of exosomes. (**C**) Analysis of the size distribution of EXOdysf with a nanoparticle tracking analysis (NTA) system. (**D**) Western blot to evaluate the presence and localization of dysferlin protein in EXOdysf. 25 μg total protein from exosomes derived from myotubes was loaded and Alix was used as an exosomal marker. Tryp, sap, or tryp+sap refer to trypsin-, saponin- or both trypsin- and saponin-treated EXOdysf.](thnov08p1243g001){#F1}

![**Examination of the restoration and localization of dysferlin protein in EXOdysf-treated murine dysferlin-deficient (DYSF^-/-^) myotubes.** The restoration of dysferlin protein was examined 48 h after the addition of 100 μg/mL EXOdysf in DYSF^-/-^ myotubes. **(A)** Western blot to measure the level of dysferlin protein in EXOdysf-treated DYSF^-/-^ myotubes. GAPDH was used as a loading control and 20 μgor 200 μg total protein from cell lysates or exosomes was loaded, respectively. **(B)** Confocal fluorescence microscopy images to reflect the localization of restored dysferlin protein in EXOdysf-treated DYSF^-/-^ myotubes. Nuclei were counterstained with DAPI (blue) (scale bar = 30μm; for boxed areas, scale bar= 15 μm). Arrowheads refer to the co-localization of caveolin-3 (red) and exosome (green).](thnov08p1243g002){#F2}

![**Functional restoration of EXOdysf-treated murine DYSF^-/-^ myotubes**. (**A**) Two-photon confocal microscopy images showing the membrane repair capacity of EXOdysf in DYSF^-/-^ myotubes. Arrowheads point to the laser injury sites. The FM4-64 dye (red) was used to show the integrity of the membrane (scale bar = 10 μm). WT: wild-type; BF: bright field. (**B**) Quantitative analysis of fluorescence intensity at different time-points in WT (circles), DYSF^-/-^ (squares) or EXOdysf-treated DYSF^-/-^ (triangles) myotubes. Significant reductions in fluorescence intensity were achieved in EXOdysf-treated DYSF^-/-^ myotubes compared to untreated myotubes (n=15, two-tailed test, \*P\<0.05). (**C**) Immunostaining of dysferlin and lysosome-associated membrane protein-1 (LAMP-1) in EXOdysf-treated DYSF^-/-^ myotubes. Nuclei were counterstained with DAPI (blue). Arrowheads point to the scrape wounding sites (scale bar =100 μm). (**D**) Two-photon confocal microscopy images showing the Ca^2+^ influx in EXOdysf-treated DYSF^-/-^ myotubes. Arrowheads point to the laser injury sites (scale bar = 10 μm). (**E**)Quantitative analysis of fluorescence intensity at different time-points in WT (circles), DYSF^-/-^ (squares) or EXOdysf-treated DYSF^-/-^ (triangles) myotubes. Significant reductions in fluorescence intensity were achieved in EXOdysf-treated DYSF^-/-^ myotubes compared to untreated myotubes at earlier time-points (n=15, two-tailed test, \*P\<0.05).](thnov08p1243g003){#F3}

![**Restoration of dysferlin protein and membrane repair capacities in human DYSF^-/-^ myotubes treated with human serum exosomes (EXOser). (A)** Western blot to examine the level of dysferlin protein in human serum exosomes. 20 μgor 50 μg total protein from cell lysates or exosomes was loaded and Cytochrome C was used as an organelle marker. EXOdysf refers to exosomes derived from normal human myotubes. **(B)** Western blot to examine the level of dysferlin restoration in human DYSF^-/-^ myotubes at 48 h after the addition of 100 μg/mL human EXOser. GAPDH was used as a loading control and 100 μg or 200 μg total protein from cell lysates or exosomes was loaded, respectively. **(C)** Two-photon confocal microscopy image showing the membrane repair capacity of EXOser-treated DYSF^-/-^ myotubes. Arrowheads point to the laser injury sites (scale bar =20 μm). **(D)** Quantitative analysis of fluorescence intensity at different time-points in WT (circles), DYSF Exon22^-/-^ or Exon55^-/-^ (squares) or EXOser-treated DYSF^-/-^ (triangles) myotubes. Significant reductions in fluorescence intensity were achieved in EXOser-treated DYSF Exon22^-/-^ or Exon55^-/-^ myotubes compared to untreated myotubes (n=15, two-tailed test, \*P\<0.05).](thnov08p1243g004){#F4}

![**Examination of dysferlin proteinin exosomes from normal controls\' and dysferlinopathic patients\' serum and urine**. (**A**) Western blot to examine levels of dysferlin protein in exosomes from normal controls\' and dysferlinopathic patients\' serum. 30 μg total protein from exosomes was loaded. Pn stands for the patient No. EXOcon refers to exosomes from normal controls\' serum. (**B**) Representative gene sequencing results for dysferlinopathic patients (patient no. 20 and her parents). (**C**) Western blot to analyze the expression of exosomes derived from a spectrum of dysferlinopathic patients\' serum. P20-F and P20-M mean patient no.20\'s father and mother. (**D**) Western blot to examine levels of dysferlin protein in exosomes from normal controls\' and dysferlinopathic patients\' urine. 50 μg total protein from exosomes was loaded. EXOcon refers to exosomes derived from normal human urine. (**E**) Western blot to analyze the expression of dysferlin in urine exosomes derived from a spectrum of dysferlinopathic patients.](thnov08p1243g005){#F5}

###### 

Clinical information for dysferlinopathic patients

  ------------------------------------------------------------------------------------------------------------
  Patient No.   Sex   DOB          Clinical diagnosis   Gene mutations                          IHC
  ------------- ----- ------------ -------------------- --------------------------------------- --------------
  **1**         M     1984-4-25    LGMD2B               c.1033+1G\>A (Intron11, het)            N/A

  **2**         F     1989-10-27   LGMD2B               c.1721T\>C (p.Leu574Pro, het)\          Dysferlin(-)
                                                        c.6241C\>T (p.Arg2081Cys, het)          

  **3**         M     1997-2-10    Miyoshi              c.959A\>T (p.Asp320Val, het)\           Dysferlin(-)
                                                        c.1721T\>C (p.Leu574Pro, het)           

  **4**         M     1974-11-25   Miyoshi              c.5905T\>C(p.Trp1969Arg, het)\          Dysferlin(-)
                                                        c.5509G\>A(p.Asp1837Asn, het)           

  **5**         M     1979-7-30    Miyoshi              c.4939G\>T(p.Glu1647Ter, het)           Dysferlin(±)

  **6**         M     1983-5-19    LGMD2B               c.3166C\>T(p.Arg1056Ter, het);\         N/A
                                                        c.1577-2A\>C(Intron17, het)             

  **7**         M     1983-9-5     LGMD2B               c.847A\>G(p.Thr283Ala,hom)              N/A

  **8**         F     1993-7-4     LGMD2B               c.1468_1469insA(p.Met490AsnfsX15,hom)   Dysferlin(-)

  **9**         F     1983-4-21    LGMD2B               c.1560delT(p.Pro520fs, het);\           Dysferlin(-)
                                                        c.3093G\>T(p.Trp1031Cys, het)           

  **10**        F     1981-4-13    LGMD2B               c.5657dupG(p.Trp1886fs,hom)             N/A

  **11**        F     1979-8-11    Miyoshi              N/A                                     Dysferlin(-)

  **12**        F     1987-1-3     Miyoshi              c.1523-1G\>A(intron17, het)\            Dysferlin(-)
                                                        c.5525G\>A(p.Gly1842Asp, het)           

  **13**        F     2002-10-1    LGMD2B               c.4532delA(p.Glu1512SerfsX13, het)\     N/A
                                                        c.5626G\>T(p.Asp1876Tyr, het)           

  **14**        F     1996-12-16   LGMD2B               c.3112C\>T(p.Arg1038Ter,hom)            Dysferlin(-)

  **15**        F     1981-11-22   LGMD2B               c.1033+1G\>A(Intron11, het)\            N/A
                                                        c.3575-1G\>T(Intron32, het)             

  **16**        M     1990-8-22    Miyoshi              c.1033+1G\>A (Intron11, het)\           N/A
                                                        c.3575-1G\>T (Intron32, het)            

  **17**        M     2001-4-23    Miyoshi              c.5830C\>T(p.Arg1944Ter, het)\          Dysferlin(-)
                                                        c.5346delG(p.Leu1782LeufsX81, het)      

  **18**        F     1989-2-28    LGMD2B               c.1461C\>A(p.Cys487Ter, het)\           N/A
                                                        c.3033delG(p.Val1011ValfsX77, het)      

  **19**        M     1988-12-10   LGMD2B               c.703C\>T(p.Arg235Ter,hom)              N/A

  **20**        F     1996-3-26    LGMD2B               c.2049G\>A(p.Trp683Ter, het)\           N/A
                                                        c.176delT(p.Leu59ArgfsX92, het)         

  **21**        M     1992-2-25    Miyoshi              c.703C\>T(p.Arg235Ter,hom)              N/A

  **22**        F     1986-10-1    Miyoshi              N/A                                     Dysferlin(-)
  ------------------------------------------------------------------------------------------------------------

\*N/A: not available; DOB: date of birth; IHC: immunohistochemistry; Dysferlin (±) means very faint staining. Miyoshi: miyoshi myopathy; LGMD2B: limb-girdle muscular dystrophy type 2B; Gene mutations: transcript accession numbers NM_001130987; 001130979; 003494.
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